Table 3. Mucosal concentrations of TFV and TFV-DP based on community state type (CST) at end of treatment (visit 7) for TFV and TFV/LNG IVR users combined.
| Variable | CST IV Microbiota | Lactobacillus spp. Dominated Microbiota (CST I, II, III, V) | P value | ||||||
|---|---|---|---|---|---|---|---|---|---|
| N | Mean | SD | Median | N | Mean | SD | Median | ||
| Tenofovir | |||||||||
| CV Aspirate (ng/mL) *106 | 11 | 4.7 | 7.0 | 1.0 | 27 | 2.4 | 1.8 | 2.5 | 0.66 |
| Tissue (ng/mg) | 21 | 169.4 | 180.2 | 120.7 | 50 | 78.0 | 88.2 | 41.7 | 0.07 |
| Tenofovir-Diphosphate | |||||||||
| Tissue (fmol/mg) | 21 | 8,038 | 9,970 | 4,098 | 48 | 3,949 | 4,773 | 2,530 | 0.27 |
| Molecular Ratio of TFV-DP to TFV (%) | 21 | 1.7 | 1.6 | 1.1 | 48 | 2.6 | 4.1 | 1.3 | 0.65 |